^
Association details:
| Biomarker: | HER-2 positive |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | trastuzumab botidotin (A166) (HER2-targeted antibody-drug conjugate, Tubulin inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A first in-human study of A166 in patients with locally advanced/metastatic solid tumors which are HER2-positive or HER2-amplified who did not respond or stopped responding to approved therapies.
Published date:
05/13/2020
Excerpt:
A166 demonstrated clinically meaningful efficacy in heavily pretreated patients with relapsed or refractory advanced solid cancers. The achievement of an ORR of 36% at efficacious dose levels and up to 100% in HER2 positive patients regardless of histology (2 CRC, 1 BC and 1 NSCLC) at the highest studied dose level exceed.
DOI:
10.1200/JCO.2020.38.15_suppl.1049
Trial ID:
